Article Text

Download PDFPDF

402 Treatment patterns post PARP inhibitor in epithelial ovarian cancer patients: results from an Australian, retrospective, multi-institute cohort study
  1. T Sivakumaran1,
  2. M Krasovitsky2,3,4,
  3. A Freimund1,5,6,
  4. K Chen Lee2,3,4,7,
  5. K Webber8,
  6. J So8,
  7. C Norris2,3,
  8. M Friedlander2,3,4,
  9. L Mileshkin1,5,6,9 and
  10. G Au-Yeung1,5,6,9
  1. 1Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
  2. 2Prince of Wales Hospital, Randwick, NSW, Australia
  3. 3Royal Hospital for Women, Randwick, NSW, Australia
  4. 4Prince of Wales Clinical School, University of New South Wales, NSW, Australia
  5. 5Royal Women
  6. 2019;s Hospital, Melbourne, VIC, Australia
  7. 6Mercy Hospital for Women, Heidelberg, VIC, Australia
  8. 7NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia
  9. 8Monash Hospital, Clayton, VIC, Australia
  10. 9Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia


Introduction PARP inhibitors (PARPi) have changed the management landscape for patients with epithelial ovarian cancer (EOC). However, as with many targeted therapies, treatment resistance is common. The response to treatment post-PARPi has not been well described in trials. Data is needed to better understand disease course, and guide treatment decisions. The primary aim is to describe the treatment patterns post-PARPi. Secondary aims are to describe patient characteristics who received chemotherapy post-PARPi and DoR to chemotherapy.

Methods Retrospective analysis of women with EOC treated with PARPi either in the maintenance or treatment setting and via government-funded or clinical trial access at six gynaecological oncology centres. Between 2007–2019 eligible women were identified via clinics, trial databases and pharmacy dispensing logs. Information regarding clinico-pathological characteristics and treatment outcomes were collated from medical records.

Results Eighty-five women with EOC were identified. 90.6% received chemotherapy post-PARPi, with 72.7% receiving platinum-based chemotherapy. Clinicopathological characteristics in table 1.

Best responses observed were 5.2% CR, 19.5% PR, 19.5% SD, and 55.8% PD. Median DOR was 7.0 months (range, 0.2 – 20.4 months) in 77 patients receiving chemotherapy post-PARPi. Eight patients did not receive further systemic therapy due to poor performance status. Women who received platinum doublet chemotherapy post-PARPi had a longer mPFS than those receiving platinum single agent or non-platinum chemotherapy (9.1 months vs 3.3 months vs 5.0 months, respectively p=0.0004).

Abstract 402 Table 1

Clinicopathological characteristics

Conclusion Most patients received-platinum based chemotherapy post-PARPi with a modest response rate. Potential overlapping mechanisms of resistance to PARPi and platinum require further study to improve patient outcomes.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.